Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: Associations with clinicopathological and molecular features

Pathology Research and Practice

Volumn 210, Issue 2, 2014, Pages 111-117

  Azzoni, Cinzia ^a   Bottarelli, Lorena ^a   Cecchini, Stefano ^a   Ziccarelli, Antonio ^a   Campanini, Nicoletta ^a   Bordi, Cesare ^a   Sarli, Leopoldo ^a   Silini, Enrico Maria ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

18qLOH; Chromosomal instability; Colorectal cancer; Thymidylate synthase; Topoisomerase I

Indexed keywords

DNA TOPOISOMERASE; FLUOROURACIL; LEVAMISOLE; PROTEIN MLH1; PROTEIN MSH2; THYMIDYLATE SYNTHASE; DNA; MICROSATELLITE DNA; TOP1 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHROMOSOMAL INSTABILITY; CHROMOSOME 18Q; CLINICAL FEATURE; COLORECTAL CANCER; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; TUMOR LOCALIZATION; VERY ELDERLY; ADENOCARCINOMA; CHROMOSOME 18; COLORECTAL TUMOR; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CHROMOSOMAL INSTABILITY; CHROMOSOMES, HUMAN, PAIR 18; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; PHENOTYPE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84892881686     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.11.004     Document Type: Article

References (71)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49:1374-1403.
3. Grady W.M., Carethers J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008, 135:1079-1099.
4. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instability in colorectal cancers. Nature 1997, 386:623-627.
5. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988, 319:525-532.
6. Pritchard C.C., Grady W.M. Colorectal cancer molecular biology moves into clinical practice. Gut 2011, 60:116-129.
7. Watanabe T., Wu T.T., Catalano P.J., Ueki T., Satriano R., Haller D.G., Benson A.B.I., Hamilton S.R. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2001, 344:1196-1206.
8. Diep C.B., Thorstensen L., Meling G.I., Skovlund E., Rognum T.O., Lothe R.A. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J. Clin. Oncol. 2003, 21:820-829.
9. Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., Hamilton S.R., Laurent-Puig P., Gryfe R., Shepherd L.E., Tu D., Redston M., Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003, 349:247-257.
10. de la Chapelle A., Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J. Clin. Oncol. 2010, 28:3380-3387.
11. Popat S., Hubner R., Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 2005, 23:608-609.
12. Jen J., Kim H., Piantadosi S., Liu Z.F., Levitt R.C., Sistonen P., Kinzler K.W., Vogelstein B., Hamilton S.R. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N. Engl. J. Med. 1994, 331:213-221.
13. Ogunbiyi O.A., Goodfellow P.J., Herforth K., Gagliardi G., Swanson P.E., Birnbaum E.H., Read T.E., Fleshman J.W., Kodner I.J., Moley J.F. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J. Clin. Oncol. 1998, 16:427-433.
14. Jernvall P., Makinen M.J., Karttunen T.J., Mäkelä J., Vihko P. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br. J. Cancer 1999, 79:903-908.
15. Lanza G., Matteuzzi M., Gafá R., Orvieto E., Maestri I., Santini A., del Senno L. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int. J. Cancer 1998, 79:390-395.
16. Choi S.W., Lee K.J., Bae Y.A., Min K.O., Kwon M.S., Kim K.M., Rhyu M.G. Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin. Cancer Res. 2002, 8:2311-2322.
17. Alazzouzi H., Alhopuro P., Salovaara R., Sammalkorpi H., Järvinen H., Mecklin J.P., Hemminki A., Schwartz S.J., Aaltonen L.A., Arango D. SMAD4 as a prognostic marker in colorectal cancer. Clin. Cancer Res. 2005, 11:2606-2611.
18. Kern S.E., Fearon E.R., Kasper W.F., Enterline J.P., Leppert M., Nakamura Y., White R., Vogelstein B., Hamilton S.R. Clinical and pathological associations with allelic loss in colorectal carcinoma. JAMA 1989, 261:3099-3103.
19. Font A., Abad A., Monzó M., Sanchez J.J., Guillot M., Manzano J.L., Piñol M., Ojanguren I., Rosell R. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis. Colon Rectum 2001, 44:549-557.
20. Laurent-Puig P., Olschwang S., Delattre O., Remvikos Y., Asselain B., Melot T., Validire P., Muleris M., Girodet J., Salmon R.J. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992, 102:1136-1141.
21. Sarli L., Bottarelli L., Bader G., Iusco D., Pizzi S., Costi R., D'Adda T., Bertolani M., Roncoroni L., Bordi C. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q. Dis. Colon Rectum 2004, 47:1467-1482.
22. Walther A., Johnstone E., Swanton C., Midgley R., Tomlinson I., Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat. Rev. Cancer 2009, 7:489-499.
23. Costi M.P., Ferrari S., Venturelli A., Calò S., Tondi D., Barlocco D. Thymidylate synthase structure, function and implication in drug discovery. Curr. Med. Chem. 2005, 12:2241-2258.
24. Edler D., Glimelius B., Hallström M., Jakobsen A., Johnston P.G., Magnusson I., Ragnhammark P., Blomgren H. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J. Clin. Oncol. 2002, 20:1721-1728.
25. Bertino J.R., Banerjee D. Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time. Clin. Cancer Res. 2003, 9:1235-1239.
26. Inoue T., Hibi K., Nakayama G., Komatsu Y., Fukuoka T., Kodera Y., Ito K., Akiyama S., Nakao A. Expression level of thymidylate synthase is a good predictor of chemosensitivity to5-fluorouracil in colorectal cancer. J. Gastroenterol. 2005, 40:143-147.
27. Jensen S.A., Vainer B., Sorensen J.B. The prognostic significance of thymidylate synthase and ihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int. J. Cancer 2007, 120:694-701.
28. Longley D.B., Mc Dermott U., Johnston P.G. Clinical significance of prognostic and predictive markers in colorectal cancer. Pharmacogenomics J. 2002, 2:209-216.
29. Gupta M., Fujimori A., Pommier Y. Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta 1995, 1262:1-14.
30. Nitiss J.L., Wang J.C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol. Pharmacol. 1996, 50:1095-1102.
31. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem. Biol. 2013, 8:82-95.
32. Kostopoulos I., Karavasilis V., Karina M., Bobos M., Xiros N., Pentheroudakis G., Kafiri G., Papakostas P., Vrettou E., Fountzilas G. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer 2009, 9:339.
33. Boonsong A., Curran S., McKay J.A., Cassidy J., Murray G.I., McLeod H.L., Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum. Pathol. 2002, 33:1114-1119.
34. Braun M.S., Richman S.D., Quirke P., Daly C., Adlard J.W., Elliott F., Barrett J.H., Selby P., Meade A.M., Stephens R.J., Parmar M.K., Seymour M.T. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol. 2008, 26:2690-2698.
35. Staley B.E., Samowitz W.S., Bronstein I.B., Holden J.A. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon. Mod. Pathol. 1999, 12:356-361.
36. Santi D.V., Mc Henry C.S., Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974, 13:471-481.
37. Assaraf Y.G. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007, 26:153-181.
38. Johnston P.G., Drake J.C., Trepel J., Allegra C.J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. 1992, 52:4306-4312.
39. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Topham C., Zaninelli M., Clingan P., Bridgewater J., Tabah-Fisch I., de Gramont A., MOSAIC Investigators Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 2004, 350:2343-2351.
40. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., Maroun J.A., Ackland S.P., Locker P.K., Pirotta N., Elfring G.L., Miller L.L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 2000, 343:905-914.
41. Kornmann M., Hebart H., Danenberg K., Goeb R., Staib L., Kron M., Henne-Bruns D., Danenberg P., Link K.H. Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: results of a randomised multicentre trial. Eur. J. Cancer 2012, 1443-1451.
42. Omura K. Advances in chemotherapy against advanced or metastatic colorectal cancer. Digestion 2008, 77:13-22.
43. Cartwright T.H. Treatment decisions after diagnosis of metastatic colorectal cancer. Clin. Colorectal Cancer 2012, 11:155-166.
44. Edge S.B., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A. AJCC Cancer Staging Manual 2010, Springer, New York.
45. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Goodman P.J., Ungerleider J.S., Emerson W.A., Tormey D.C., Glick J.H., et al. Levamisole and fluouracil for adjuvant treatment of resected colon cancer. N. Engl. J. Med. 1990, 322:352-358.
46. Pahlman L. Pre-opreative treatment of rectal cancer. Management of Colorectal Cancer 1998, 153-166. Martin Dunitz, London. H. Bleiberg, P. Rougier, H.-J. Wilke (Eds.).
47. Johnston P.G., Liang C.M., Henry S., Chabner B.A., Allegra C.J. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res. 1991, 24:6668-6676.
48. Ricciardiello L., Ceccarelli C., Angiolini G., Pariali M., Chieco P., Paterini P., Biasco G., Martinelli G.N., Roda E., Bazzoli F. High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. Clin. Cancer Res. 2005, 11:4234-4240.
49. Azzoni C., Bottarelli L., Cecchini S., Silini E.M., Bordi C., Sarli L. Sporadic colorectal carcinomas with low-level microsatellite instability: a distinct subgroup with specific clinicopathological and molecular features. Int. J. Colorectal Dis. 2011, 26:445-453.
50. Samowitz W.S., Slattery M.L., Potter J.D., Leppert M.F. BAT-26 and BAT-40 instability in colorectal adenomas and carcinomas and germline polymorphisms. Am. J. Pathol. 1999, 154:1637-1641.
51. Halling K.C., French A.J., McDonnell S.K., Burgart L.J., Schaid D.J., Peterson B.J., Moon-Tasson L., Mahoney M.R., Sargent D.J., O'Connell M.J., Witzig T.E., Farr G.H.J., Goldberg R.M., Thibodeau S.N. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J. Natl. Cancer Inst. 1999, 91:1295-1303.
52. Arribas R., Ribas M., Risques R.A., Masramon L., Tórtola S., Marcuello E., Aiza G., Miró R., Capellà G., Peinado M.A. Prospective assessment of allelic losses at 4p 14-16 in colorectal cancer: two mutational patterns and a locus associated with poorer survival. Clin. Cancer Res. 1999, 5:3454-3459.
53. Umar A., Boland C., Terdiman J., Syngal S., de la Chapelle A., Rüschoff J., Fishel R., Lindor N.M., Burgart L.J., Hamelin R., Hamilton S.R., Hiatt R.A., Jass J., Lindblom A., Lynch H.T., Peltomaki P., Ramsey S.D., Rodriguez-Bigas M.A., Vasen H.F., Hawk E.T., Barrett J.C., Freedman A.N., Srivastava S. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 2004, 96:261-268.
54. Beckmann M.W., Picard F., An H.X., van Roeyen C.R., Dominik S.I., Mosny D.S., Schnurch H.G., Bender H.G., Niederacher D. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br. J. Cancer 1996, 73:1220-1226.
55. Mueller J.D., Haegle N., Keller G., Mueller E., Saretzky G., Bethke B., Stolte M., Höfler H. Loss of heterozygosity and microsatellite instability in de novo versus ex-adenoma carcinomas of the colorectum. Am. J. Pathol. 1998, 153:1977-1984.
56. Hsiang Y., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilized topoiosmerse I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989, 49:5077-5082.
57. Horisberger K., Erben P., Muessle B., Woernle C., Stroebel P., Kaehler G., Wenz F., Hochhaus A., Post S., Willeke F., Hofheinz R.D., MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren) Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs 2009, 20:519-524.
58. Bertagnolli M.M., Redston M., Compton C.C., Niedzwiecki D., Mayer R.J., Goldberg R.M., Colacchio T.A., Saltz L.B., Warren R.S. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer-a study of CALGB 9581 and 89803. J. Clin. Oncol. 2011, 29:3153-3162.
59. Gouveris P., Lazaris A.C., Papathomas T.G., Nonni A., Kyriakou V., Delladetsima J., Patsouris E.S., Tsavaris N. Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy. J. Cancer Res. Clin. Oncol. 2007, 133:1011-1015.
60. Martínez-López E., Abad A., Font A., Monzó M., Ojanguren I., Pifarré A., Sánchez J.J., Martín C., Rosell R. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998, 114:1180-1187.
61. Pietra N., Sarli L., Costi R., Ouchemi C., Grattarola M., Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis. Colon Rectum 1998, 41:1127-1133.
62. Bisgaard M.L., Jäger A.C., Dalgaard P., Søndergaard J.O., Rehfeld J.F., Nielsen F.C. Allelic loss of chromosome 2p 21-16.3 is associated with reduced survival in sporadic colorectal cancer. Scand. J. Gastroenterol. 2001, 36:405-409.
63. Lenz H.J., Danenberg K.D., Leichman C.G., Florentine B., Johnston P.G., Groshen S., Zhou L., Xiongm Y.P., Danenberg P.V., Leichman L.P. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin. Cancer Res. 1998, 4:1227-1234.
64. Sanguedolce R., Vultaggio G., Sanguedolce F., Modica G., Li Volsi F., Diana G., Guereio G., Bellanca L., Rausa L. The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res. 1998, 18:1515-1520.
65. Goldberg R.M., Sargent D., Mahoney M.R. Limited prognostic importance of immunohistochemical parameters (IHP) [thymidylate synthase (TS), KI-67, and P53] in 465 patients with Dukes' B2 and C colon cancer enrolled on North Central Cancer Treatment Group (NCCTG) trials. Proc ASCO 1998, 18:267.
66. Tsourouflis G., Theocharis S.E., Sampani A., Giagini A., Kostakis A., Kouraklis G. Prognostic and predictive value of thymidylate synthase expression in colon cancer. Dig. Dis. Sci. 2008, 53:1289-1296.
67. Donada M., Bonin S., Nardon E., De Pellegrin A., Decorti G., Stanta G. Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability. Cancer Res. Clin. Oncol. 2011, 137:201-210.
68. Odin E., Wettergren Y., Nilsson S., Carlsson G., Gustavsson B. Colorectal carcinomas with microsatellite instability display increased thymidylate synthase gene expression levels. Clin. Colorectal Cancer 2007, 6:720-727.
69. Okon K., Klimkowska A., Wójcik P., Osuch C., Papla B., Stachura J. High thymidylate synthase expression is typical for sporadic MSI-H colorectal carcinoma. Pol. J. Pathol. 2006, 57:29-33.
70. Sinicrope F.A., Rego R.L., Halling K.C., Foster N.R., Sargent D.J., La Plant B., French A.J., Allegra C.J., Laurie J.A., Goldberg R.M., Witzig T.E., Thibodeau S.N. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin. Cancer Res. 2006, 12:2738-2744.
71. Popat S., Wort R., Houlston R.S. Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance. BMC Cancer 2006, 6:150.